[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. We are currently witnessing the introduction of a new mode of hypoglycemic treatment through induction of glycosuria to decrease the availability of the metabolic substrate, i.e. glucose. Clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors are as efficacious as other oral hypoglycemic drugs. This article discusses the basic features of this new treatment concept and the efficacy and safety of this new drug group.
Servicio de Endocrinología y Nutrición, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. Electronic address: didacmauricio@gmail.com.
Dídac
D
Mauricio
D000327:Adsorption / Q000187:drug effects; D000818:Animals; D001559:Benzhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D001693:Biological Transport, Active / Q000187:drug effects; D000068896:Canagliflozin; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism*; D005960:Glucosides / Q000494:pharmacology / Q000627:therapeutic use; D006027:Glycosides / Q000494:pharmacology / Q000627:therapeutic use; D006029:Glycosuria / Q000139:chemically induced; D006030:Glycosuria, Renal / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000378:metabolism*; D027845:Malus / Q000737:chemistry; D010695:Phlorhizin / Q000302:isolation & purification / Q000627:therapeutic use; D008517:Phytotherapy; D024301:Plant Bark / Q000737:chemistry; D051381:Rats; D051297:Sodium-Glucose Transporter 2 / Q000235:genetics / Q000502:physiology*; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D001559:Benzhydryl Compounds; D015507:Drugs, Investigational; D005960:Glucosides; D006027:Glycosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; D000068896:Canagliflozin; C529054:dapagliflozin; C572941:ipragliflozin; C575681:(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol; D010695:Phlorhizin; C570240:empagliflozin; D005947:Glucose
Diabetes mellitus tipo 2; Efficacy; Eficacia; Glucosuria; Glycosuria; Inhibidores del cotransportador sodio/glucosa tipo 2; Safety; Seguridad; Type 2 diabetes mellitus; Type 2 sodium/glucose co-transporter inhibitors